Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Smoking 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma, Mantle-Cell 1Genetic Diseases, Inborn 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 3Radiotherapy 3Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Radiation Dose Hypofractionation 2Radiation 2Observation 2Metformin 2pembrolizumab 1exemestane 1afimoxifene 1Tablets 1Surgical Procedures, Operative 1Steroids 1Specimen Handling 1Protons 1Proton Therapy 1Petrolatum 1Nutrition Assessment 1Neoadjuvant Therapy 1Mastectomy, Segmental 1Mammography 1Magnetic Resonance Spectroscopy 1Letrozole 1Biopsy, Needle 1Biopsy, Large-Core Needle 1Anastrozole 14,17 beta-dihydroxy-4-androstene-3-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Intraductal, Noninfiltrating × Tablets × Clear all
NCT06033092 2025-08-28

TOLERANT

European Institute of Oncology

Phase 2 Active not recruiting
200 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡